

SUPPLEMENT

Supplementary Table 1. Distribution of patients per country, sex, and age

Characteristic	Patients (n)
Sex	
Female	9
Male	21
Age in years	
20-39	6
40-59	9
60-79	10
80-89	5
Exposure time in weeks	
<12	6
12-26	4
26-52	6
52-104	12
>104	2
Country	
Australia	1
Germany	3
France	10
Ireland	3
The Netherlands	10
Switzerland	1
United Kingdom	2

Supplementary Table 2. All Adverse Events during the Early Access Program

System Organ Class (SOC)	Reported SAEs in preferred terms	Reported AEs in preferred terms
Blood and lymphatic system disorders	<i>Lymphopenia</i>	-
Eye disorders	<i>Age-related macular degeneration</i>	-
	<i>Metamorphopsia</i>	
	<i>Retinal oedema</i>	
	<i>Visual acuity reduced</i>	
General disorders and administration site conditions	-	<i>Drug ineffective</i>
		<i>Malaise</i>
Infections and infestations	<i>COVID-19</i>	-
	<i>Klebsiella infection</i>	
	<i>Staphylococcal bacteraemia</i>	
	<i>Urosepsis</i>	
Injury, poisoning and procedural complications	-	<i>Product dose omission issue</i>
		<i>Therapy interrupted</i>
Musculoskeletal and connective tissue disorders	-	<i>Muscle disorder</i>
Nervous system disorders	-	<i>Dysgeusia</i>
Renal and urinary disorders	<i>Acute kidney injury</i>	-
	<i>End stage renal disease</i>	
	<i>Renal failure</i>	

	<i>Renal impairment</i>	
Reproductive system and breast disorders	<i>Prostatitis</i>	
Skin and subcutaneous tissue disorders		<i>Rash erythematous</i>
Surgical and medical procedures	<i>Therapy interrupted</i>	
Vascular disorders	<i>Haemorrhage</i>	<i>Flushing</i>
<i>Total</i>	<i>15</i>	<i>9</i>